EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Gross Profit
EyePoint Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Gross Profit
$41.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is EyePoint Pharmaceuticals Inc's Gross Profit?
Gross Profit
41.4m
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Gross Profit amounts to 41.4m USD.
What is EyePoint Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 3Y
13%
Over the last year, the Gross Profit growth was 25%. The average annual Gross Profit growth rates for EyePoint Pharmaceuticals Inc have been 13% over the past three years .